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Summary
 
To study the biologic role of migration inhibitory factor (MIF), a pleiotropic cytokine, we
generated a mouse strain lacking MIF by gene targeting in embryonic stem cells. Analysis of
the role of MIF during sepsis showed that MIF
 
2
 
/
 
2
 
 mice were resistant to the lethal effects of
high dose bacterial lipopolysaccharide (LPS), or 
 
Staphylococcus aureus
 
 enterotoxin B (SEB) with
 
d
 
-galactosamine and had lower plasma levels of tumor necrosis factor 
 
a
 
 (TNF-
 
a
 
) than did
wild-type mice, but normal levels of interleukin (IL)-6 and IL-10. When stimulated with LPS
and interferon 
 
g
 
, macrophages from MIF
 
2
 
/
 
2
 
 mice showed diminished production of TNF-
 
a
 
,
normal IL-6 and IL-12, and increased production of nitric oxide. MIF
 
2
 
/
 
2
 
 animals cleared
gram-negative bacteria 
 
Pseudomonas aeruginosa
 
 instilled into the trachea better than did wild-
type mice and had diminished neutrophil accumulation in their bronchoalveolar fluid com-
pared to the wild-type mice. Thioglycollate elicited peritoneal exudates in uninfected MIF
 
2
 
/
 
2
 
mice, but showed normal neutrophil accumulation. Finally, the findings of enhanced resistance
to 
 
P. aeruginosa
 
 and resistance to endotoxin-induced lethal shock suggest that the counteraction
or neutralization of MIF may serve as an adjunct therapy in sepsis.
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M
 
acrophage migration inhibitory factor (MIF)
 
1
 
 is a
pleiotropic cytokine released by macrophages, T
cells, and the pituitary gland during inflammatory responses
(1, 2). It has been shown to act as a proinflammatory cy-
tokine, playing a major role in endotoxin shock (3) and
counter-regulating the antiinflammatory effects of dexa-
methasone (4). Antibodies to MIF diminish the manifesta-
tions of autoimmunity in certain experimental models (5,
6). Furthermore, recent studies have shown that MIF en-
hances resistance to the pathogen 
 
Leishmania major
 
 (7, 8). Its
ubiquitous expression (9) and developmental regulation
(10, 11) suggest that MIF might have functions beyond the
immune system.
To study the role of MIF, we generated a mouse strain
lacking MIF by gene targeting in embryonic stem cells and
analyzed mechanisms of sepsis using these MIF
 
2
 
/
 
2
 
 mice.
Sepsis triggered by gram-negative and gram-positive bacte-
rial infection is a major cause of death of hospitalized pa-
tients (12). Endotoxin induces MIF release from macro-
phages and pituitary cells, as well as in vivo. MIF has been
shown to be released in large quantities and found in the
serum of mice after challenge with LPS (3, 13). A critical
role of MIF in endotoxemia was suggested by the observa-
tion that recombinant MIF enhanced LPS-induced lethal-
ity, whereas anti-MIF antibodies had a protective effect (3).
In this study, we describe the generation of MIF
 
2
 
/
 
2
 
 mice
and characterize the specific role of MIF in sepsis.
 
Materials and Methods
 
Targeting Vector Construction and Generation of MIF
 
2
 
/
 
2
 
 Mice.
 
A mouse 
 
Mif
 
 genomic fragment was isolated from a 129SV/J ge-
nomic library (14), and a 6.1-kb XbaI fragment containing the 5
 
9
 
upstream region, exons 1–3, and the 3
 
9
 
 region was subcloned in
pBluescript. The vector was digested with EcoRV (sites present
in the 3
 
9
 
 region of the gene and in the polylinker of the plasmid),
releasing a 0.7-kb fragment. The vector was religated and di-
gested with AgeI, disrupting part of exon 2, the second intron,
and exon 3. The 
 
neo
 
r
 
 cassette was inserted by blunt ligation after
end-filling the vector and the 
 
neo
 
r
 
 cassette. The disrupted ge-
nomic vector was digested with XbaI/XhoI and ligated into the
HSV-TK vector. The targeting vector was linearized with XhoI,
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; ES, embry-
onic stem; MIF, migration inhibitory factor; NO, nitric oxide; SEB,
 
Staphylococcus aureus
 
 enterotoxin B. 
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MIF Gene–deficient Mice
 
and 30 
 
m
 
g was transfected by electroporation into 10
 
7
 
 J1 embry-
onic stem (ES) cells that were maintained on a feeder layer of 
 
neo
 
r
 
embryonic fibroblasts in the presence of 500 U/ml of leukemia
inhibitory factor. After 8 d of selection with G418 (200 
 
m
 
g/ml)
and FIAU (2 
 
m
 
M), 30 clones were analyzed by Southern blot hy-
bridization using the 0.7-kb EcoRV/XbaI 3
 
9
 
 fragment as a probe.
One clone displayed a novel 7-kb XbaI allele predicted to occur
after homologous recombination. This heterozygous ES cell line
was injected into day 3.5 C57BL/6 blastocysts, and the blasto-
cysts were transferred into pseudopregnant females. Chimeric
mice were bred with C57BL/6 mice and agouti offspring were
analyzed for the 
 
Mif
 
 disrupted allele by Southern blot hybridiza-
tion.
 
LPS-induced Shock and Cytokine Measurement.
 
8–12-wk-old,
sex-matched MIF
 
1
 
/
 
1
 
, MIF
 
1
 
/
 
2
 
, and MIF
 
2
 
/
 
2
 
 mice from heterozy-
gous matings were injected intraperitoneally with 25 mg/kg of
LPS from 
 
Escherichia coli
 
 serotype O111:B4 (Sigma Chemical
Co.). This dose was based on previous experiments in C57BL/6
mice that gave a 50–60% lethal dose. The mice were monitored
for signs of endotoxemia at least twice daily for 5 d. For deter-
mining the plasma cytokine levels, mice similarly treated were
killed by CO
 
2
 
 at 90 min and bled by cardiac puncture. Plasma
from three mice was pooled within each group. Two to three
pools from each group were measured by ELISA.
 
Shock Induced with LPS, TNF-
 
a
 
, and Staphylococcus Enterotoxin B
with 
 
D
 
-galactosamine.
 
Mice were injected intraperitoneally with
a mixture of 20 mg/mouse of 
 
d
 
-galactosamine (Sigma Chemical
Co.) and 1 
 
m
 
g/mouse of LPS (
 
E. coli
 
 type as above), 1 
 
m
 
g/mouse
TNF-
 
a
 
 (PharMingen), or 37 mg/kg of 
 
Staphylococcus aureus
 
 en-
terotoxin B (SEB; Toxin Technology). Susceptible mice all died
in 
 
,
 
24 h.
 
Macrophage Cultures.
 
Macrophages elicited for 4 d with thio-
glycollate or resident macrophages were obtained by peritoneal
lavage using 10 ml of PBS. 10
 
6
 
 cells in 1 ml of RPMI/10% FCS
supplemented with glutamine, 
 
b
 
-ME, amino acids, penicillin,
and streptomycin were cultured in 24-well plates in triplicate.
After 2 h at 37
 
8
 
C in 5% CO
 
2
 
, nonadherent cells were removed
by washing. Cell activation was performed by the addition of
fresh media containing 100 
 
m
 
g of LPS and 100 U/ml of IFN-
 
g
 
(PharMingen) followed by incubation for 24 h. Supernatants were
collected and frozen at 
 
2
 
20
 
8
 
C for subsequent analysis. For bacte-
ricidal assays, resident macrophages were prepared as described
above and cultured in media with LPS and IFN-
 
g
 
 for 20 h; after
washing with PBS, RPMI with 10% mouse serum without anti-
biotics was added with 10
 
7
 
 CFU/ml 
 
Listeria monocytogenes.
 
 After
30 min, all plates were washed. 1 ml of PBS with 0.05% Triton
X-100 was added to wells of the 0 time point. The other wells
were incubated in RPMI with 10% FCS and 5 
 
m
 
g/ml of genta-
mycin for 2 or 6 h and the cells were lysed as above. 
 
Listeria
 
 kill-
ing was determined by counting the number of CFU per well.
 
Cytokine and Nitric Oxide Assays.
 
TNF-
 
a
 
, IL-6, IL-10, and
IL-12 from plasma or cell culture supernatants were measured by
ELISA using reagents from PharMingen following the manufac-
turer’s directions. MIF ELISA was performed with reagents from
R & D Systems, Inc. To evaluate nitric oxide (NO), NO
 
3
 
2
 
 and
NO
 
2
 
2
 
 were measured from cell culture supernatants using
Griess’s assay (15).
 
Lung Infection with Pseudomonas aeruginosa.
 
The mucoid 
 
P.
aeruginosa
 
 strain A01 was used and maintenance of stocks and
methods used were as previously described (16). Mice matched in
age and gender (8–10 wk) were anesthetized with Ketamine (90
mg/kg) and Xylazine (10 mg/kg) (both from Sigma Chemical
Co.). 
 
P. aeruginosa
 
 (3.5 
 
3
 
 10
 
6
 
), freshly grown in tryptic soy broth
 
for 18 h, were instilled into the trachea in a volume of 50 
 
m
 
l. The
lung clearance of 
 
P. aeruginosa
 
 was measured by killing mice im-
mediately and at 6 and 24 h after 
 
P. aeruginosa
 
 instillation. Lungs
were excised and homogenized in 3 ml of ice-cold sterile distilled
water. Homogenates were diluted appropriately in sterile PBS,
cultured overnight in brain-heart infusion agar plates, and the
number of CFU was determined. Results are expressed as CFU 6
h/CFU 0 h and CFU 24 h/CFU 0 h.
To assess microvascular injury and neutrophil accumulation, 100
 
m
 
l of Evans blue (6.25 mg/ml) was administered intravenously 2 h
after 
 
P. aeruginosa
 
 instillation, and bronchoalveolar lavage (BAL) 
 
3
 
 1
ml was performed 6 h after bacterial instillation. The recovered BAL
fluid was assessed for total cell counts using a standard hemocytome-
ter, and differential cell counts were determined from Dif-Quick–
stained (Dade Diagnostics) cytospin preparations. Permeability
changes were determined by comparing the leakage of Evans blue
into the BAL fluid to the amount remaining in the plasma (17).
 
Results and Discussion
 
Production and Characterization of MIF
 
2
 
/
 
2
 
 Mice.
 
The mouse
MIF gene was disrupted by replacing part of exons 2 and 3
with a 
 
neo
 
r
 
 cassette (Fig. 1 A). The targeting vector was elec-
troporated into J1 ES cells and G418-FIAU–resistant colonies
were isolated. The average frequency of homologous recom-
bination was about 1 in 30 resistant colonies. Correctly tar-
geted ES cells were used to generate chimeric animals by
injection into C57BL/6 blastocysts. Highly chimeric animals
transmitted the mutated allele through the germline, and
homozygous mice were generated by intercrosses of hetero-
zygous mice (Fig. 1 B). Northern blot analysis from liver
RNA of LPS-treated animals confirmed that the gene dis-
ruption created a null mutation (Fig. 1 C). ELISA of serum
from LPS-treated animals further confirmed the absence of
MIF protein in the MIF
 
2
 
/
 
2
 
 mice (Fig. 1 D). Of the 218 ani-
mals obtained from heterozygous matings, 16% were homo-
zygous for the null allele. The newborn MIF
 
2
 
/
 
2
 
 mice devel-
oped normally in size and behavior and were fertile. The
litter size of heterozygous and homozygous matings were
normal. Both gross examination and histopathological analysis
of several organs (kidney, liver, spleen, adrenal, thymus,
lungs, heart, brain, and intestine) of MIF
 
2
 
/
 
2
 
 mice revealed
no abnormalities. Flow cytometric analysis of splenocytes and
thymocytes of MIF
 
2
 
/
 
2
 
 mice demonstrated normal lympho-
cyte populations (data not shown).
 
Response to High-dose LPS: Survival and Cytokines.
 
To
analyze the role of MIF in endotoxemia, MIF
 
2
 
/
 
2
 
, MIF
 
1
 
/
 
2
 
,
and wild-type mice were injected intraperitoneally with a
high dose of LPS (25 mg/kg). MIF deficiency conferred a
remarkable resistance to the lethal effects of LPS (Fig. 2 A).
However, MIF
 
2
 
/
 
2
 
 mice still exhibited signs of endotox-
emia a few h after LPS treatment, including piloerection,
shivering, and lethargy, although these signs appeared
milder than in control mice. Since a cascade of inflamma-
tory mediators triggered by LPS is important in the patho-
genesis of endotoxic shock (18, 19), we measured cytokine
levels in the plasma of MIF
 
2
 
/
 
2
 
 mice compared with wild-
type 90 min after LPS challenge. There was a 50% reduc-
tion in the plasma levels of TNF-a but similar levels of IL-6343 Bozza et al.
Figure 2. MIF-deficient mice are more resistant to LPS-induced lethality and have less plasma TNF-a. (A) Survival curves of mice that received 25
mg/kg LPS intraperitoneally. (B) Plasma levels of cytokines at 90 min after LPS. *P , 0.001.
and IL-10 (Fig. 2 B). The observed resistance to LPS could
be partially due to the diminished TNF-a production sec-
ondary to lack of MIF (13); to an enhanced antiinflamma-
tory effect of stress-induced steroids no longer counter-reg-
ulated by MIF (4); or to possible other proinflammatory
properties of MIF which have yet to be determined.
Cytokines and NO of Macrophages from MIF2/2 Mice.
Macrophages were studied as they are critically involved in
the pathogenesis of endotoxemia (20). Furthermore, MIF
and TNF-a have been shown to work in an autocrine/
paracrine fashion; i.e., MIF increases macrophage TNF-a,
which in turn increases MIF release (13). To study the ef-
fect of MIF deficiency on macrophage activation, thiogly-
collate-elicited peritoneal macrophages were stimulated
with LPS and IFN-g for 6, 12, 18, and 24 h, and the super-
natants were analyzed. Macrophages from MIF2/2 mice
showed a marked decrease in TNF-a (P , 0.001; Fig. 3 A).
However, MIF2/2 macrophages were able to produce
IL-12 and IL-6 (Fig. 3, B and C). These results show that
MIF is required for the optimal production of TNF-a dur-
ing endotoxemia. The lowered plasma levels of TNF-a are
probably at least partially due to diminished production by
macrophages.
It has been shown that recombinant MIF enhances NO
production in vitro by macrophages stimulated with IFN-g
(21). Furthermore, attenuated Salmonella transfected with
the MIF gene alone, or in combination with TNF-a or
IFN-g administered orally to susceptible mice, reduced L.
major infection and enhanced NO production (7). Surpris-
ingly, there was a significant increase (P , 0.005) in NO in
the MIF2/2 macrophages stimulated with LPS and IFN-g
(Fig. 3 D). These results suggest that endogenous macro-
phage MIF either dampens NO production by these cells
or increases its turnover.
Response to TNF-a, LPS, and SEB by MIF2/2 Mice Re-
ceiving D-galactosamine. To further analyze the role of MIF
in lethal endotoxemia, we took advantage of mouse models
that have been developed to closely mimic the high sensi-
tivity of humans to the toxic effects of bacterial products.
Hepatocytes from mice sensitized with d-galactosamine
have a transcriptional arrest and become highly susceptible
to the cytotoxic action of TNF-a (22, 23). The reduction
Figure 1. Disruption of the Mif gene in mice. (A) Gene-targeting strategy: structure and partial restriction maps of Mif gene,
targeting vector, mutated allele, and probe used for Southern blot hybridization. (B) Southern blot analysis of tail DNA from
MIF1/1, MIF1/2, and MIF2/2 mice. The 6.1-kb wild-type and the 7-kb target XbaI fragments were identified using the
0.7-kb EcoRV/XbaI probe shown in A. (C) Northern blot hybridization of liver RNA obtained from wild-type and MIF2/2
mice 1 h after intraperitoneal treatment with 500 mg of LPS was performed using probes for MIF and b-actin. (D) ELISA shows
absence of MIF protein in the supernatants obtained from MIF2/2 spleen cells 72 h after stimulation with Con A (1 mg/ml).344 MIF Gene–deficient Mice
of TNF-a found in MIF2/2 mice suggested that MIF acted
upstream from TNF-a but might still be involved in the
toxic effect of TNF-a. However, injection of a lethal dose
of TNF-a (1 mg/mouse) with d-galactosamine killed all
five wild-type and all five MIF2/2 mice (Table I), indicat-
ing that MIF is not required for the lethal effects of TNF-a.
Although MIF2/2 mice were resistant to a high dose of
LPS (Fig. 2 A), they were susceptible to a combination of
low-dose LPS and d-galactosamine; all five mice in each
group died (Table I). Indeed, it has been shown that the
mechanisms leading to death are different in models using
high or low doses of LPS (24).
Further studies showed that MIF2/2 mice were resistant
to the lethal effects of another bacterial product, SEB, with
d-galactosamine. All five wild-type mice died from SEB in-
jected intraperitoneally whereas all five MIF2/2 mice lived.
SEB acts as a superantigen for T cells, resulting in the re-
lease of inflammatory cytokines involved in toxic shock
(25). Sera taken 90 min after SEB showed 65% less TNF-a
in MIF2/2 than in wild-type mice, 140 6 25 and 396 6 89
pg/ml, respectively (6 SE, P , 0.05). These results indicate
that MIF plays a critical role in superantigen-induced toxic
shock in which T cells play a major role.
It is interesting to note that the phenotype of intracellu-
lar adhesion molecule (ICAM)-1–deficient mice is similar,
showing resistance to high doses of LPS as well as low
doses of SEB with d-galactosamine, and susceptibility to a
combination of a low dose of LPS and d-galactosamine
(26). ICAM-1–deficient mice have reduced transendothe-
lial leukocyte migration but normal TNF-a levels in re-
sponse to LPS. However, the mechanisms of action in this
phenotype are different for MIF2/2 mice, as the latter have
reduced TNF-a production and no impairment of leuko-
cyte migration to the peritoneum elicited by thioglycollate
(mean neutrophil count after 4 h was 6.71 6 2.23 3 106
and 11.9 6 2.15 3 106 in wild-type (n 5 3) and MIF2/2
(n 5 4) mice, respectively, P , 0.1).
Response of MIF2/2 Mice to Infection. To determine the
role of MIF in host defense to gram-negative bacteria, P.
aeruginosa were instilled intratracheally into MIF2/2 and
wild-type mice. The MIF2/2 mice efficiently cleared bac-
teria from the lungs 24 h after infection, having almost 3
log fewer bacteria than heterozygous or wild-type controls
(MIF2/2 9.3 6 4.0 3 103, versus combined MIF1/1 and
MIF1/2 2.1 6 0.9 3 106, P , 0.03, Fig. 4 A). Of interest,
there was a significant decrease in neutrophils in the BAL at
6 h in the MIF2/2 mice compared to controls, 55.3 6 7.6 3
105 versus 95.9 6 13.5 3 105, (n 5 6, P , 0.04); Fig. 4 B.
This is consistent with the report that anti-MIF antibody
diminishes LPS-induced neutrophil migration to the lungs
and BAL fluid as well as the level of macrophage protein 2,
a powerful neutrophil chemokine (27).
Inflammation has usually been thought to be a necessary
part of the host’s defense against microorganisms, some-
thing the body must accept to successfully defend itself.
However, the findings reported here, along with the en-
hanced bacterial clearing and diminished inflammation in
mice lacking the CD14 receptor for endotoxin (28), sug-
gest that host defense is more efficient without certain LPS-
induced inflammatory cytokines. Indeed, IL-1 and TNF-a
can enhance the growth and invasiveness of pathogenic
gram-negative bacteria (29, 30). Moreover, MIF has been
found in the alveolar airspaces of patients with adult respi-
ratory distress syndrome (ARDS), and increases the secre-
tion of proinflammatory cytokines from alveolar cells (31).
We have initiated studies on MIF2/2 mice to determine
the effect of MIF on other infectious agents. In a prelimi-
nary experiment using the gram-positive bacteria L. mono-
cytogenes, MIF2/2 mice were not more susceptible than
wild-type controls. Furthermore, peritoneal macrophages
Figure 3. Stimulated macrophages from MIF-deficient mice produce
less TNF-a but more NO. Thioglycollate-elicited macrophages were
stimulated with 100 mg/ml of LPS and 100 U/ml of IFN-g. Supernatants
were removed at 6, 12, 18, and 24 h and tested for (A) TNF-a, (B) IL-
12, (C) IL-6, and (D) NO. Similar results were obtained in three other
experiments at 24 h.
Table I. Effect of LPS, TNF, or SEB in Conjunction with 
D-galactosamine
Dose 1/1 (dead/total) 2/2 (dead/total)
LPS 1 mg/mouse 5/5 5/5
TNF-a 1 mg/mouse 5/5 5/5
SEB 37 mg/kg 5/5 0/5
Mice were injected intraperitoneally with d-galactosamine, 20 mg/
mouse in conjunction with LPS, TNF-a, or SEB. Mice were observed
for 3 d and the lethal effect was seen within 24 h.345 Bozza et al.
obtained from MIF2/2 mice and stimulated with IFN-g
and LPS were able to kill intracellular L. monocytogenes as
well as wild-type macrophages (data not shown). In con-
trast, MIF2/2 mice were more susceptible than wild-type
mice to the intracellular parasite L. major. Lymph node cells
from infected MIF2/2 mice showed higher IL-4 produc-
tion after antigen stimulation than did those from wild-type
animals, suggesting that MIF plays a role in Th1/Th2
balance (our unpublished results).
Taken together, our results show that MIF plays a critical
role in endotoxic shock and SEB toxicity without hamper-
ing the ability of mice to clear gram-negative or -positive
infections. Indeed, the increased resistance to the gram-
negative bacterial product LPS, as well as the enhanced
ability to clear P. aeruginosa infections in the lungs in MIF2/2
mice, indicates that neutralization or counteraction of MIF
might constitute an adjunct therapy for the treatment of
sepsis. Further studies with this animal model should clarify
the role of MIF in immunity, inflammation, and other bio-
logic functions.
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